-- TC Energy (TRP.TO) 周五发布的报告显示，该公司第一季度可比盈利同比增长。 可比盈利为 10.3 亿加元，合每股 0.99 加元，高于去年同期的 9.83 亿加元，合每股 0.95 加元。该业绩超过了 FactSet 汇总的非 GAAP 每股收益预期 0.97 加元。 可比 EBITDA 为 30.9 亿美元，高于去年同期的 27.1 亿美元。 该公司重申了其 2026 年可比 EBITDA 预期，为 116 亿美元至 118 亿美元。预计 2026 年的可比 EBITDA 和可比每股收益将高于 2025 年，这与 TC Energy 2025 年年度报告的预测一致。 预计资本支出在扣除少数股东权益调整前为60亿至65亿美元，净资本支出为55亿至60亿美元。 此外，TC Energy已批准阿巴拉契亚天然气供应项目，该项目是对其哥伦比亚天然气系统的扩建，旨在提供高达每日8亿立方英尺的天然气输送能力，以促进新增天然气发电项目的发展。 该项目预计将于2030年投入运营，预计耗资约15亿美元。 TC Energy董事会宣布，截至6月30日的季度，每股普通股派发0.8775美元的季度股息，年化股息为3.51美元。股息将于7月31日支付给截至6月30日营业结束时登记在册的股东。
Related Articles
Research
Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
$INCY
Australia
GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease
GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%
$GSK
International
ISM US Manufacturing Index Indicates Steady Expansion in April
The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.